ES2091737T3 - Formulaciones farmaceuticas de fluoxetina. - Google Patents

Formulaciones farmaceuticas de fluoxetina.

Info

Publication number
ES2091737T3
ES2091737T3 ES95304975T ES95304975T ES2091737T3 ES 2091737 T3 ES2091737 T3 ES 2091737T3 ES 95304975 T ES95304975 T ES 95304975T ES 95304975 T ES95304975 T ES 95304975T ES 2091737 T3 ES2091737 T3 ES 2091737T3
Authority
ES
Spain
Prior art keywords
pharmaceutical formulations
fluoxetina
dispersible tablets
formulations
appropriate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95304975T
Other languages
English (en)
Other versions
ES2091737T1 (es
Inventor
Mendizabal Flavia Arce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly SA
Original Assignee
Lilly SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8286976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2091737(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly SA filed Critical Lilly SA
Publication of ES2091737T1 publication Critical patent/ES2091737T1/es
Application granted granted Critical
Publication of ES2091737T3 publication Critical patent/ES2091737T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN FORMULACIONES FARMACEUTICAS DE FLUOXETINA O UNA SAL DE ADICION ACIDA DE LA MISMA ADECUADAS PARA LA MANUFACTURA DE TABLETAS DISPERSIBLES MEDIANTE COMPRESION DIRECTA Y QUE COMPRENDEN ADEMAS DEL INGREDIENTE ACTIVO, LOS EXCIPIENTES Y COADYUDANTES APROPIADOS, QUE SE SELECCIONAN ENTRE DESINTEGRANTES, DILUYENTES, LUBRICANTES, ANTIADHERENTES, ENDULZANTES, SABORIZANTES Y OPCIONALMENTE, COLORANTES. LAS FORMULACIONES SON ADECUADAS PARA MANUFACTURAR TABLETAS DISPERSIBLES QUE SE DESINTEGRAN EN MENOS DE TRES MINUTOS EN AGUA ENTRE 19 (GRADOS) Y 21 (GRADOS) C Y SON APROPIADAS PARA EL TRATAMIENTO DE LA DEPRESION.
ES95304975T 1994-07-20 1995-07-17 Formulaciones farmaceuticas de fluoxetina. Expired - Lifetime ES2091737T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401593A ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.

Publications (2)

Publication Number Publication Date
ES2091737T1 ES2091737T1 (es) 1996-11-16
ES2091737T3 true ES2091737T3 (es) 2001-06-01

Family

ID=8286976

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09401593A Expired - Fee Related ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.
ES95304975T Expired - Lifetime ES2091737T3 (es) 1994-07-20 1995-07-17 Formulaciones farmaceuticas de fluoxetina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09401593A Expired - Fee Related ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.

Country Status (31)

Country Link
US (1) US5747068A (es)
EP (3) EP1070501A1 (es)
JP (1) JPH0840884A (es)
KR (1) KR100360130B1 (es)
CN (2) CN1440745B (es)
AT (1) ATE200733T1 (es)
AU (2) AU692550B2 (es)
BR (1) BR9503386A (es)
CO (1) CO4410195A1 (es)
CY (1) CY2241B1 (es)
CZ (1) CZ287378B6 (es)
DE (2) DE693281T1 (es)
DK (1) DK0693281T3 (es)
ES (2) ES2082723B1 (es)
FI (3) FI121262B (es)
GR (2) GR960300064T1 (es)
HK (1) HK1012573A1 (es)
HU (1) HU228859B1 (es)
IL (1) IL114641A (es)
MY (1) MY114776A (es)
NO (1) NO312225B2 (es)
NZ (1) NZ272610A (es)
PE (1) PE33996A1 (es)
PL (1) PL181359B1 (es)
PT (1) PT693281E (es)
RU (1) RU2145850C1 (es)
SI (1) SI0693281T1 (es)
TR (1) TR199500878A2 (es)
TW (1) TW404840B (es)
UA (1) UA41346C2 (es)
ZA (1) ZA956074B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0869772T1 (en) * 1995-12-27 2002-04-30 Janssen Pharmaceutica N.V. Bioadhesive solid dosage form
DK1166651T3 (da) * 1996-02-29 2005-05-30 Fujisawa Pharmaceutical Co Hurtigt disintegrerende granulat af et syntetisk södemiddel indeholdende kiselsyre og/eller siliciumdioxid
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
AU740757B2 (en) * 1997-10-09 2001-11-15 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
JP4504467B2 (ja) * 1998-07-30 2010-07-14 佐藤製薬株式会社 口腔内崩壊性錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
BR0209283A (pt) * 2001-05-01 2004-07-13 Pfizer Prod Inc Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (es) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DE602006011150D1 (de) * 2005-05-17 2010-01-28 Actelion Pharmaceuticals Ltd Dispergierbare bosertan-tablette
CN100353943C (zh) * 2005-07-04 2007-12-12 广州固志医药科技有限公司 乳酸氟罗沙星分散片及其制备方法
NZ565846A (en) * 2005-07-18 2011-12-22 Horizon Therapeutics Inc Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
FR2891147B1 (fr) 2005-09-28 2007-12-07 Ethypharm Sa Comprimes orodispersibles de principes actifs amers
EP1993377B1 (en) * 2006-03-03 2012-01-04 Symrise AG Pressed agglomerates suitable for consumption having retarded aroma release
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
EP2155159B1 (en) * 2007-05-08 2019-07-10 Hercules LLC Robust rapid disintegration tablet formulation
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR101438629B1 (ko) 2013-02-04 2014-09-05 현대자동차 주식회사 체결 장치 및 그 제어 방법
DK3087989T3 (en) * 2013-12-27 2019-03-25 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE TOFOGLIFLOZINE AND PROCEDURES FOR PRODUCING THEREOF
KR102598782B1 (ko) * 2014-10-03 2023-11-07 노파르티스 아게 알펠리십을 포함하는 제약 조성물
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法
KR102453105B1 (ko) * 2020-10-26 2022-10-07 현대제철 주식회사 침지노즐 크리닝 장치
CN114699374B (zh) * 2022-04-01 2024-02-20 佛山市南海东方澳龙制药有限公司 一种猫犬专用盐酸氟西汀固体制剂及其制备和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3091574A (en) * 1961-09-05 1963-05-28 Bristol Myers Co Tablet disintegrants
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
NL159577B (nl) * 1968-02-15 1979-03-15 Organon Nv Werkwijze ter bereiding van snel desintegrerende vaste vormstukken.
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
JPS6056659A (ja) * 1983-09-08 1985-04-02 Yanmar Diesel Engine Co Ltd 農用トラクタ−のブレ−キ装置
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4844908A (en) * 1986-11-27 1989-07-04 Duphar International Research B.V. Method of preparing tablets with clovoxamine fumarate and tablets thus prepared
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8921069D0 (en) * 1989-09-18 1989-11-01 Wellcome Found Pharmaceutically active compound,preparation and use
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
EP0449561A3 (en) * 1990-03-29 1992-04-01 Eli Lilly And Company Use of (r)-norfluoxetine in the preparation of a medicament with affinity to 5ht1c receptors
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DK0612242T3 (da) * 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法

Also Published As

Publication number Publication date
TW404840B (en) 2000-09-11
AU707210B2 (en) 1999-07-08
GR960300064T1 (en) 1996-11-30
CZ287378B6 (en) 2000-11-15
UA41346C2 (uk) 2001-09-17
PL309721A1 (en) 1996-01-22
EP1072262A1 (en) 2001-01-31
DK0693281T3 (da) 2001-05-21
US5747068A (en) 1998-05-05
AU692550B2 (en) 1998-06-11
ZA956074B (en) 1996-05-14
HUT75036A (en) 1997-03-28
DE69520768T2 (de) 2001-08-23
GR3035788T3 (en) 2001-07-31
ATE200733T1 (de) 2001-05-15
CZ188095A3 (en) 1996-02-14
KR100360130B1 (ko) 2003-01-29
MY114776A (en) 2003-01-31
TR199500878A2 (tr) 1996-06-21
CN1440745B (zh) 2012-03-21
AU8317498A (en) 1998-11-05
HU9502154D0 (en) 1995-09-28
IL114641A0 (en) 1995-11-27
EP0693281A2 (en) 1996-01-24
CN1101187C (zh) 2003-02-12
CN1123142A (zh) 1996-05-29
NZ272610A (en) 1997-08-22
DE693281T1 (de) 1997-04-03
ES2082723A1 (es) 1996-03-16
NO952863D0 (no) 1995-07-19
IL114641A (en) 1999-04-11
EP0693281A3 (en) 1996-10-30
BR9503386A (pt) 1996-02-27
RU2145850C1 (ru) 2000-02-27
PL181359B1 (pl) 2001-07-31
FI20011852A (fi) 2001-09-20
FI121262B (fi) 2010-09-15
AU2509895A (en) 1996-02-01
EP1070501A1 (en) 2001-01-24
CY2241B1 (en) 2003-07-04
SI0693281T1 (en) 2001-12-31
NO952863L (no) 1996-01-22
CN1440745A (zh) 2003-09-10
HK1012573A1 (en) 1999-08-06
NO312225B1 (no) 2002-04-15
ES2091737T1 (es) 1996-11-16
EP0693281B1 (en) 2001-04-25
ES2082723B1 (es) 1996-10-01
JPH0840884A (ja) 1996-02-13
PT693281E (pt) 2001-08-30
NO312225B2 (no) 2002-04-15
KR960003720A (ko) 1996-02-23
FI953515A (fi) 1996-01-21
CO4410195A1 (es) 1997-01-09
HU228859B1 (en) 2013-06-28
PE33996A1 (es) 1996-09-09
DE69520768D1 (de) 2001-05-31
FI953515A0 (fi) 1995-07-20
FI20011851A (fi) 2001-09-20

Similar Documents

Publication Publication Date Title
ES2091737T3 (es) Formulaciones farmaceuticas de fluoxetina.
TW262461B (es)
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
DE69905368D1 (en) Oxydiertes thymosin beta 4
EP2767291A3 (en) Treatment of glycogen storage disease type II
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
NO994431L (no) Ny formulering
BR9504573A (pt) Formulaçao farmaceutica adequada para fabricaçao de tabletes dispersiveis por compressao direta tablete de cefaclor dispersivel e processo para fabricaçao de um tablete dispersivel contendo cefaclor
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
EP1595879A3 (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693281

Country of ref document: ES